251 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information Shareholder information Share capital and control Details of our issued share capital and the number of shares held Share buy-back programme in Treasury as at 31 December 2018 can be found in Note 33 to The Board has been authorised to issue and allot Ordinary Shares the financial statements, Share capital and share premium account.
under Article 9 of the companys Articles of Association.
The power under Article 9 and the authority for the company to make purchases Our Ordinary Shares are listed on the London Stock Exchange of its own shares are subject to shareholder authorities which are and are also quoted on the New York Stock Exchange NYSE sought on an annual basis at our Annual General Meeting AGM.
in the form of American Depositary Shares ADS.
Each ADS Any shares purchased by the company may be cancelled or held represents two Ordinary Shares.
For details of listed debt and as Treasury shares or used for satisfying share options and grants where it is listed refer to Note 31 to the financial statements, under Group employee share plans.
Our programme covers purchases of shares for cancellation or Holders of Ordinary Shares and ADS are entitled to receive to be held as Treasury shares, in accordance with the authority dividends when declared, the companys Annual Report, to attend renewed by shareholders at the AGM in May 2018, when the and speak at general meetings of the company, to appoint proxies company was authorised to purchase a maximum of just under and to exercise voting rights.
Details of shares purchased, those cancelled, There are no restrictions on the transfer, or limitations on the holding, those held as Treasury shares and those subsequently transferred of Ordinary Shares and ADS and no requirements to obtain approval from Treasury to satisfy awards under the Groups employee share prior to any transfers.
No Ordinary Shares or ADS carry any special plans are disclosed in Note 33 to the financial statements, Share rights with regard to control of the company and there are no capital and share premium account.
Major shareholders have the same In determining specific share repurchase levels, the company voting rights per share as all other shareholders.
There are no considers the development of free cash flow during the year.
known arrangements under which financial rights are held by No shares were purchased during the financial years ended 2015, a person other than the holder of the shares and no known 2016, 2017 or 2018. agreements on restrictions on share transfers or on voting rights.
The company confirms that it does not currently intend to make Shares acquired through the Groups employee share plans rank any market purchases in 2019.
The company will review the equally with the other shares in issue and have no special rights.
potential for future share buy-backs in line with its usual annual The trustees of our Employee Share Ownership Plan trusts have cycle and subject to return and ratings criteria.
waived their rights to dividends on shares held by those trusts.
Market capitalisation Exchange controls and other limitations affecting security holders The market capitalisation, based on shares in issue excluding Other than certain economic sanctions, which may be in force Treasury shares, of GSK at 31 December 2018 was 73.23 billion.
from time to time, there are currently no applicable laws, decrees At that date, GSK was the fifth largest company by market or regulations in force in the UK restricting the import or export of capitalisation in the FTSE index.
capital or affecting the remittance of dividends or other payments to holders of the companys shares who are non-residents of the UK.
Share price 2018 2017 2016 Similarly, other than certain economic sanctions which may be in force from time to time, there are no limitations relating only to At 1 January 13.23 15.62 13.73 non-residents of the UK under English law or the companys At 31 December 14.91 13.23 15.62 Articles of Association on the right to be a holder of, and to vote Decrease increase 12.7% 15.3 % 13.8% in respect of, the companys shares.
High during the year 16.22 17.22 17.23 Interests in voting rights Low during the year 12.43 12.76 13.44 Other than as stated below, as far as we are aware, there are no The table above sets out the middle market closing prices.
The persons with significant direct or indirect holdings in the company.
companys share price increased by 12.7% in 2018.
This compares Information provided to the company pursuant to the Financial with a decrease in the FTSE 100 index of 12.5% during the year.
Conduct Authoritys FCA Disclosure Guidance and Transparency The share price on 1 March 2019 was 15.10.
Rules DTRs is published on a Regulatory Information Service and on the companys website, www.
UK US$ The company had received notifications in accordance with the 75 18 FCAs DTRs of the following notifiable interests in the voting rights 17 70 in the companys issued share capital: 16 65 31 December 2018 1 March 2019 60 15 Percentage Percentage No.
of of issued 55 14 shares capital % shares capital % 13 50 BlackRock, Inc 348,328,939 7.02 359,325,075 7.24 12 45 Percentage of Ordinary shares in issue, excluding Treasury shares.
11 40 We have not acquired or disposed of any interests in our own 35 10 shares during the period under review, with the exception of those 09 30 transferred from Treasury to satisfy awards under the Groups 31 12 15 31 12 16 31 12 17 31 12 18 employee share plans.
UK share price UK US ADS price US$ 252 GSK Annual Report 2018 Shareholder information continued Share capital and control continued Nature of trading market The following tables set out, for the periods indicated, the high and low middle market closing quotations in pence for the shares on the London Stock Exchange, and the high and low closing prices in US dollars for the ADS on the NYSE.
Ordinary Shares representing the companys ADS programme, which is managed by the Depositary, are registered in the name of BNY Nominees Limited.
At 1 March 2019, BNY Nominees Limited held 934,362,581 Ordinary Shares representing 18.81% of the issued share capital excluding Treasury shares at that date.
At 1 March 2019, the number of holders of Ordinary Shares in the US was 974 with holdings of 994,696 Ordinary Shares, and the number of registered holders of ADS was 21,197 with holdings of 467,181,290 ADS.
Certain of these Ordinary Shares and ADS were held by brokers or other nominees.
As a result, the number of holders of record or registered holders in the US is not representative of the number of beneficial holders or of the residence of beneficial holders.
